Obesity Drug Race: Eli Lilly Leads, Pharma M&A Urgently Needed

Obesity Drug Market Landscape

• 👑 Eli Lilly is positioned as the leader in the obesity drug market, with a clean liver profile for its oral candidate and effective injectable amalin that minimizes muscle mass loss.
• ⚠️ Novo Nordisk is considered the second-best, holding 33% of the market, but has faced repeated setbacks with disappointing trial data for its drug.
• 📉 Amgen experienced a significant stock drop following disappointing results for its monthly weight loss shot, Maritide, due to side effects and patient discontinuations.

Pharma Company Valuations and M&A

• 💰 Pharma multiples have decreased, with the average now around 10x, making current valuations potentially misleading, especially for companies like Amgen.
• ⏳ Many large pharmaceutical companies, including Merck and Bristol Myers, face significant revenue cliffs with over 50% of their revenue disappearing by the end of the decade.
• 🚀 M&A activity is crucial for big pharma to address revenue degradation and pipeline gaps, with a strong need for acquisitions, particularly in the obesity drug space.
• 🤝 Even companies like Pfizer, which has completed six deals since the pandemic, are actively seeking more assets.

Biotech vs. Traditional Pharma

• 📊 While biotech has seen some recovery, there are still issues to resolve. However, the revenue degradation in traditional pharma necessitates M&A activity involving biotech assets.
• 💡 Investors are increasingly looking at biotech ETFs like XBI or IBB, sensing a shift in the market environment with more potential catalysts, including M&A.